Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 4Recurrence 2Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Hematologic Diseases 1Disease Progression 1Disease 1Blood Protein Disorders 1

Interventions

Lenalidomide 4Dexamethasone 4Bortezomib 3pomalidomide 2Cyclophosphamide 2ricolinostat 1Zoledronic Acid 1Vitamin D 1Transplantation, Autologous 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Calcium Dobesilate 1Calcium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × ricolinostat × Plasma cell × Clear all
NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡